Stockscreener 앱 받기
45.38
9.89%
-4.98
시간 외 거래:
45.50
0.12
+0.26%
전일 마감가:
$50.36
열려 있는:
$45
하루 거래량:
2.36M
Relative Volume:
1.97
시가총액:
$3.60B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-7.6397
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-12.95%
1개월 성능:
-4.76%
6개월 성능:
-8.27%
1년 성능:
+39.85%
1일 변동 폭
$45.00
$48.36
1주일 범위
$45.00
$52.86
52주 변동 폭
$29.02
$58.38
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.38 | 4.07B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Earnings Update: PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Momentum Screeners Rank PTC Therapeutics Inc. in Top 5 TodayCommunity Strategy With High Win Rate Backtested - metal.it
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's Why - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $79.00 at Wells Fargo & Company - MarketBeat
PTC Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 10,739 Shares - MarketBeat
PTC Therapeutics: Pioneering a New Growth Cycle in Rare Disease Innovation - AInvest
PTC Therapeutics and the Launch of Sephience™: A Catalyst-Driven Play in Rare Disease Innovation - AInvest
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches - MSN
Federated Hermes Inc. Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Beat Expectations But Shares Still Dropped - Finimize
PTC Therapeutics price target lowered to $70 from $72 at Baird - TipRanks
Transcript : PTC Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
PTC Therapeutics stock price target raised to $63 from $60 at RBC Capital - Investing.com Canada
PTC Therapeutics stock price target raised to $56 from $52 at TD Cowen - Investing.com Canada
RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating - MarketScreener
PTC Projects Confidence In Sephience Launch With Royalty Buyback - insights.citeline.com
Earnings call transcript: PTC Therapeutics beats Q2 2025 EPS expectations By Investing.com - Investing.com Nigeria
Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating - MarketScreener
Ptc Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 34.6% - AInvest
PTC Therapeutics: A Strategic Pivot to Sephience and the Path to Sustained Growth - AInvest
PTC Therapeutics Q2 Loss Narrows, Revenue Declines; Sets Full-Year Revenue Guidance - 富途牛牛
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Highlights: St - GuruFocus
PTC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Reports Q2 2025 Financial Results - TipRanks
PTC Therapeutics Q2 2025 Earnings Preview - MSN
PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions - TipRanks
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics (PTCT): A Strategic Assessment of Growth Catalysts and Profitability Potential Post-Sephience Approval - AInvest
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Citizen Tribune
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
PTC Therapeutics: Q2 Earnings Snapshot - Stamford Advocate
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
PTC Therapeutics Enters Rights Satisfaction Agreement - TipRanks
PTC Therapeutics Announces Q2 2025 Financial Results - TipRanks
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06) - TipRanks
PTC THERAPEUTICS Earnings Results: $PTCT Reports Quarterly Earnings - Quiver Quantitative
PTC Therapeutics Inc Surpasses Revenue Estimates with $179 Million in Q2 2025; Sephience Launch Marks Strategic Milestone - GuruFocus
PTC Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
PTC Therapeutics: Pioneering Rare Disease Innovation with a Diversified Pipeline and Strategic Growth Catalysts - AInvest
JPMorgan raises PTC Therapeutics stock price target to $68 on Sephience demand - Investing.com Canada
PTC Therapeutics: Strategic Shift and Robust Financials Drive Buy Rating with $68 Target by 2025 - TipRanks
PTC Therapeutics Earnings Preview: Analysts Expect $-1.07 EPS, Historical Performance and Stock Performance - AInvest
PTC Therapeutics Earnings Preview - 富途牛牛
Westfield Capital Management Co. LP Acquires New Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Inc. stock retracement – recovery analysisBuy Strategy Tracker with Growth Indicators - Newser
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday - MarketBeat
Q3 Earnings Estimate for PTCT Issued By William Blair - MarketBeat
What recovery options are there for PTC Therapeutics Inc.Free Growth Based Investment Plan Guidance - Newser
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):